Expression of antigen processing and presenting molecules in brain metastasis of breast cancer

Cancer Immunology, Immunotherapy

Volumn 61, Issue 6, 2012, Pages 789-801

  Liu, Yan ^a,b   Komohara, Yoshihiro ^c   Domenick, Natalie ^a   Ohno, Masasuke ^a,b   Ikeura, Maki ^a   Hamilton, Ronald L ^a,b   Horbinski, Craig ^d   Wang, Xinhui ^b   Ferrone, Soldano ^b   Okada, Hideho ^a,b  

^a UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^b UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^c KUMAMOTO UNIVERSITY   (Japan)

^d UNIVERSITY OF KENTUCKY   (United States)

Author keywords

Antigen processing machinery (APM) components; Brain metastasis; Breast cancer; CD8 + T cell; Transporter associated with antigen processing (TAP)1

Indexed keywords

BETA 2 MICROGLOBULIN; CALNEXIN; HLA ANTIGEN CLASS 1; MEMBRANE PROTEIN; SHORT HAIRPIN RNA; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 1; TRANSPORTER ASSOCIATED WITH ANTIGEN PROCESSING 2; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN PRESENTATION; ARTICLE; BRAIN METASTASIS; BREAST CANCER; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; LYMPHOCYTIC INFILTRATION; MAJOR CLINICAL STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL;

ANIMALS; ANTIGEN PRESENTATION; ATP-BINDING CASSETTE TRANSPORTERS; BETA 2-MICROGLOBULIN; BRAIN NEOPLASMS; BREAST NEOPLASMS; CALNEXIN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HUMANS; IMMUNOHISTOCHEMISTRY; IMMUNOLOGIC SURVEILLANCE; LYMPHOCYTES, TUMOR-INFILTRATING; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, TRANSGENIC;

EID: 84862337169     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-011-1137-9     Document Type: Article

References (55)

1. Barnholtz-Sloan JS, Sloan AE, Davis FG, Vigneau FD, Lai P, Sawaya RE (2004) Incidence proportions of brain metastases in patients diagnosed (1973 to 2001) in the metropolitan detroit cancer surveillance system. J Clin Oncol 22(14):2865-2872. doi:10.1200/jco.2004.12.149 (Pubitemid 41079905)
2. Patel RR, Mehta MP (2007) Targeted therapy for brain metastases: improving the therapeutic ratio. Clin Cancer Res 13(6):1675-1683. doi:10.1158/1078-0432.ccr-06-2489 (Pubitemid 46952932)
3. Weil RJ, Palmieri DC, Bronder JL, Stark AM, Steeg PS (2005) Breast cancer metastasis to the central nervous system. Am J Pathol 167(4):913-920 (Pubitemid 41416243)
4. Lin NU, Bellon JR, Winer EP (2004) CNS metastases in breast cancer. J Clin Oncol 22(17):3608-3617. doi:10.1200/jco.2004.01.175 (Pubitemid 41103668)
5. Stemmler H-J, Heinemann V (2008) Central nervous system metastases in HER-2-overexpressing metastatic breast cancer: a treatment challenge. Oncologist 13(7):739-750. doi:10.1634/theoncologist.2008-0052
6. Kennecke H, Yerushalmi R, Woods R, Cheang MCU, Voduc D, Speers CH, Nielsen TO, Gelmon K (2010) Metastatic behavior of breast cancer subtypes. J Clin Oncol 28(20):3271-3277. doi:10.1200/jco.2009.25.9820
7. Martin JJ, Kondziolka D (2005) Indications for resection and radiosurgery for brain metastases. Curr Opin Oncol 17(6):584-587 (Pubitemid 41566412)
8. Kondziolka D, Kano H, Harrison GL, Yang H-C, Liew DN, Niranjan A, Brufsky AM, Flickinger JC, Lunsford LD (2010) Stereotactic radiosurgery as primary and salvage treatment for brain metastases from breast cancer. J Neurosurg. doi:10.3171/2010.8.JNS10461
9. Okada H, Kohanbash G, Zhu X, Kastenhuber ER, Hoji A, Ueda R, Fujita M (2009) Immunotherapeutic approaches for glioma. Crit Rev Immunol 29(1):1-42
10. + T-cell responses against novel glioma-associated antigen peptides and clinical activity by vaccinations with α-type 1 polarized dendritic cells and polyinosinic-polycytidylic acid stabilized by lysine and carboxymethylcellulose in patients with recurrent malignant glioma. J Clin Oncol 29(3):330-336. doi:10.1200/jco.2010.30.7744
11. Campoli M, Ferrone S (2008) HLA antigen changes in malignant cells: epigenetic mechanisms and biologic signiWcance. Oncogene 27(45):5869-5885
12. Cabrera T, Maleno I, Collado A, Lopez Nevot MA, Tait BD, Garrido F (2007) Analysis of HLA class I alterations in tumors: choosing a strategy based on known patterns of underlying molecular mechanisms. Tissue Antigens 69:264-268. doi:10.1111/j.1399-0039.2006.00777.x (Pubitemid 46625898)
13. Cathro H, Smolkin M, Theodorescu D, Jo V, Ferrone S, Frierson H (2010) Relationship between HLA class I antigen processing machinery component expression and the clinicopathologic characteristics of bladder carcinomas. Cancer Immunol Immunother 59(3):465-472. doi:10.1007/s00262-009-0765-9
14. RaVaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre ML, Cama A, Basso G, Ferrone S, Gambini C, Pistoia V (2007) Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res 67(11):5471-5478. doi:10.1158/0008-5472.can-06-4735
15. Vitale M, Rezzani R, Rodella L, Zauli G, Grigolato P, Cadei M, Hicklin DJ, Ferrone S (1998) HLA class I antigen and transporter associated with antigen processing (TAP1 and TAP2) down-regulation in high-grade primary breast carcinoma lesions. Cancer Res 58(4):737-742 (Pubitemid 28099486)
16. Overwijk WW, Tsung A, Irvine KR, Parkhurst MR, Goletz TJ, Tsung K, Carroll MW, Liu C, Moss B, Rosenberg SA, Restifo NP (1998) gp100/pmel 17 is a murine tumor rejection antigen: induction of "self"-reactive, tumoricidal T cells using high-aYnity, altered peptide ligand. J Exp Med 188(2):277-286. doi:10.1084/jem.188.2.277 (Pubitemid 28357756)
17. Stam N, Spits H, Ploegh H (1986) Monoclonal antibodies raised against denatured HLA-B locus heavy chains permit biochemical characterization of certain HLA-C locus products. J Immunol 137(7):2299-2306 (Pubitemid 16020728)
18. Perosa F, Luccarelli G, Prete M, Favoino E, Ferrone S, Dammacco F (2003) {beta}2-microglobulin-free HLA class I heavy chain epitope mimicry by monoclonal antibody HC-10-speciWc peptide. J Immunol 171(4):1918-1926 (Pubitemid 36966475)
19. Sernee MF, Ploegh HL, Schust DJ (1998) Why certain antibodies cross-react with HLA-A and HLA-G: epitope mapping of two common MHC class I reagents. Mol Immunol 35(3):177-188 (Pubitemid 28319923)
20. Maio M, Altomonte M, Tatake R, ZeV RA, Ferrone S (1991) Reduction in susceptibility to natural killer cell-mediated lysis of human FO-1 melanoma cells after induction of HLA class I antigen expression by transfection with B2m gene. J Clin Investig 88(1):282-289
21. Bandoh N, Ogino T, Cho HS, Hur SY, Shen J, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2005) Development and characterization of human constitutive proteasome and immuno-proteasome subunit-speciWc monoclonal antibodies. Tissue Antigens 66(3):185-194. doi:10.1111/j.1399-0039.2005.00462.x (Pubitemid 41243306)
22. Wang X, Campoli M, Cho HS, Ogino T, Bandoh N, Shen J, Hur SY, Kageshita T, Ferrone S (2005) A method to generate antigen-specific mAb capable of staining formalin-Wxed, paraYn-embedded tissue sections. J Immunol Methods 299(1-2):139-151 (Pubitemid 40725931)
23. Ogino T, Wang X, Kato S, Miyokawa N, Harabuchi Y, Ferrone S (2003) Endoplasmic reticulum chaperone-speciWc monoclonal antibodies for Xow cytometry and immunohistochemical staining. Tissue Antigens 62:385-393. doi:10.1034/j.1399-0039.2003.00114.x (Pubitemid 37338878)
24. Fujita M, Zhu X, Sasaki K, Ueda R, Low KL, Pollack IF, Okada H (2008) Inhibition of STAT3 promotes the eYcacy of adoptive transfer therapy using type-1 CTLs by modulation of the immunological microenvironment in a murine intracranial glioma. J Immunol 180(4):2089-2098
25. Racanelli V, Leone P, Frassanito MA, Brunetti C, Perosa F, Ferrone S, Dammacco F (2010) Alterations in the antigen processingpresenting machinery of transformed plasma cells are associated with reduced recognition by CD8+ T cells and characterize the progression of MGUS to multiple myeloma. Blood 115(6):1185-1193. doi:10.1182/blood-2009-06-228676
26. Zhai Y, Yang JC, Spiess P, Nishimura MI, Overwijk WW, Roberts B, Restifo NP, Rosenberg SA (1997) Cloning and characterization of the genes encoding the murine homologues of the human melanoma antigens MART1 and gp100. J Immunother 20(1):15-25 (Pubitemid 28011520)
27. le Doussal V, Tubiana-Hulin M, Hacene K, Friedman S, Brunet M (1989) Nuclear characteristics as indicators of prognosis in node negative breast cancer patients. Breast Cancer Res Treat 14(2):207-216. doi:10.1007/bf01810737 (Pubitemid 20001933)
28. Atkins D, Breuckmann A, Schmahl GE, Binner P, Ferrone S, Krummenauer F, Störkel S, Seliger B (2004) MHC class I antigen processing pathway defects, ras mutations and disease stage in colorectal carcinoma. Int J Cancer 109(2):265-273. doi:10.1002/ijc.11681 (Pubitemid 38240930)
29. Bandoh N, Ogino T, Katayama A, Takahara M, Katada A, Hayashi T, Harabuchi Y (2010) HLA class I antigen and transporter associated with antigen processing downregulation in metastatic lesions of head and neck squamous cell carcinoma as a marker of poor prognosis. Oncol Rep 23(4):933-939
30. Kloetzel P-M (2004) The proteasome and MHC class I antigen processing. Biochimica et Biophysica Acta (BBA) Mol Cell Res 1695(1-3):225-233
31. Hansen TH, Bouvier M (2009) MHC class I antigen presentation: learning from viral evasion strategies. Nat Rev Immunol 9(7):503-513
32. Seliger B (2008) Molecular mechanisms of MHC class I abnormalities and APM components in human tumors. Cancer Immunol Immunother 57(11):1719-1726. doi:10.1007/s00262-008-0515-4
33. Mehling M, Simon P, Mittelbronn M, Meyermann R, Ferrone S, Weller M, Wiendl H (2007) WHO grade associated downregulation of MHC class I antigen-processing machinery components in human astrocytomas: does it reXect a potential immune escape mechanism? Acta Neuropathol 114(2):111-119. doi:10.1007/s00401-007-0231-8 (Pubitemid 47103522)
34. Lopez-Albaitero A, Nayak JV, Ogino T, Machandia A, Gooding W, DeLeo AB, Ferrone S, Ferris RL (2006) Role of antigen-processing machinery in the in vitro resistance of squamous cell carcinoma of the head and neck cells to recognition by CTL. J Immunol 176(6):3402-3409 (Pubitemid 43363987)
35. Lou Y, Vitalis TZ, Basha G, Cai B, Chen SS, Choi KB, JeVries AP, Elliott WM, Atkins D, Seliger B, JeVeries WA (2005) Restoration of the expression of transporters associated with antigen processing in lung carcinoma increases tumor-speciWc immune responses and survival. Cancer Res 65(17):7926-7933. doi:10.1158/0008-5472.can-04-3977 (Pubitemid 41297271)
36. Lou Y, Basha G, Seipp RP, Cai B, Chen SS, Moise AR, JeVries AP, Gopaul RS, Vitalis TZ, JeVeries WA (2008) Combining the antigen processing components TAP and tapasin elicits enhanced tumor-free survival. Clin Cancer Res 14(5):1494-1501. doi:10.1158/1078-0432.ccr-07-1066 (Pubitemid 351413934)
37. + αβT cells: a prevalent tumor-reactive T-cell subset in metastatic colorectal cancers. Int J Cancer 128(12):2923-2932. doi:10.1002/ijc.25640
38. Han LY, Fletcher MS, Urbauer DL, Mueller P, Landen CN, Kamat AA, Lin YG, Merritt WM, Spannuth WA, Deavers MT, De Geest K, Gershenson DM, Lutgendorf SK, Ferrone S, Sood AK (2008) HLA class I antigen processing machinery component expression and intratumoral T-cell inWltrate as independent prognostic markers in ovarian carcinoma. Clin Cancer Res 14(11):3372-3379. doi:10.1158/1078-0432. ccr-07-4433
39. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, Tosolini M, Camus M, Berger A, Wind P, Zinzindohoue F, Bruneval P, Cugnenc PH, Trajanoski Z, Fridman WH, Pages F (2006) Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science 313(5795):1960-1964 (Pubitemid 44498003)
40. Yang I, Tihan T, Han SJ, Wrensch MR, Wiencke J, Sughrue ME, Parsa AT (2010) CD8+ T-cell inWltrate in newly diagnosed glioblastoma is associated with long-term survival. J Clin Neurosci 17(11):1381-1385
41. Lohr J, RatliV T, Huppertz A, Ge Y, Dictus C, Ahmadi R, Grau S, Hiraoka N, Eckstein V, Ecker RC, KorV T, von Deimling A, Unterberg A, Beckhove P, Herold-Mende C (2011) EVector T-cell inWltration positively impacts survival of glioblastoma patients and is impaired by tumor-derived TGF-beta. Clin Cancer Res 17(13):4296-4308. doi:10.1158/1078-0432.CCR-10-2557
42. He H, Somlo G, Yun Y, Chu PG (2009) Dendritic cell inWltration in lymph node positive breast carcinomas. Breast J 15(2):218-220. doi:10.1111/j.1524- 4741.2009.00707.x
43. + T cells. Virchows Arch 459(4):391-398. doi:10.1007/s00428- 011-1145-3
44. Zhang J, Patel L, Pienta KJ (2010) CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev 21(1):41-48. doi:10.1016/j.cytogfr.2009.11.009
45. Mantovani A, Savino B, Locati M, Zammataro L, Allavena P, Bonecchi R (2010) The chemokine system in cancer biology and therapy. Cytokine Growth Factor Rev 21(1):27-39. doi:10.1016/j.cytogfr.2009.11.007
46. Pagès F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, Mlecnik B, Kirilovsky A, Nilsson M, Damotte D, Meatchi T, Bruneval P, Cugnenc P-H, Trajanoski Z, Fridman W-H, Galon J (2005) EVector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med 353(25):2654-2666. doi:10.1056/NEJMoa051424 (Pubitemid 41817714)
47. Lott ST, Chen N, Chandler DS, Yang Q, Wang L, Rodriguez M, Xie H, Balasenthil S, Buchholz TA, Sahin AA, Chaung K, Zhang B, Olufemi S-E, Chen J, Adams H, Band V, El-Naggar AK, Frazier ML, Keyomarsi K, Hunt KK, Sen S, HaVty B, Hewitt SM, Krahe R, Killary AM (2009) DEAR1 is a dominant regulator of acinar morphogenesis and an independent predictor of local recurrence-free survival in early-onset breast cancer. PLoS Med 6(5):e1000068
48. Varga D, Koenig J, Kuhr K, Strunz K, Geyer V, Kurzeder C, Atassi Z, Blettner M, Kreienberg R, Woeckel A (2010) Comparison of early onset breast cancer patients to older premenopausal breast cancer patients. Arch Gynecol Obstet 282(4):427-432. doi:10.1007/s00404-009-1339-y
49. Bauer K, Parise C, Caggiano V (2010) Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 10(1):228
50. Van Belle V, Van Calster B, Brouckaert O, Vanden Bempt I, Pintens S, Harvey V, Murray P, Naume B, Wiedswang G, Paridaens R, Moerman P, Amant F, Leunen K, Smeets A, Drijkoningen M, Wildiers H, Christiaens M-R, Vergote I, Van HuVel S, Neven P (2010) Qualitative assessment of the progesterone receptor and HER2 improves the Nottingham Prognostic Index up to 5 years after breast cancer diagnosis. J Clin Oncol 28(27):4129-4134. doi:10.1200/jco.2009.26.4200
51. Dunnwald L, Rossing M, Li C (2007) Hormone receptor status, tumor characteristics, and prognosis: a prospective cohort of breast cancer patients. Breast Cancer Res 9(1):R6
52. Sari E, Guler G, Hayran M, Gullu I, Altundag K, Ozisik Y (2011) Comparative study of the immunohistochemical detection of hormone receptor status and HER-2 expression in primary and paired recurrent/metastatic lesions of patients with breast cancer. Med Oncol 28(1):57-63. doi:10.1007/s12032-010- 9418-2
53. Gong Y, Han EY, Guo M, Pusztai L, Sneige N (2011) Stability of estrogen receptor status in breast carcinoma. Cancer 117(4):705-713. doi:10.1002/cncr. 25506
54. Herrmann F, Lehr H-A, Drexler I, Sutter G, Hengstler J, Wollscheid U, Seliger B (2004) HER-2/neu-mediated regulation of components of the MHC class I antigen-processing pathway. Cancer Res 64(1):215-220. doi:10.1158/0008-5472.can- 2522-2 (Pubitemid 38114101)
55. Mimura K, Ando T, Poschke I, Mougiakakos D, Johansson CC, Ichikawa J, Okita R, Nishimura MI, Handke D, Krug N, Choudhury A, Seliger B, Kiessling R (2011) T cell recognition of HLAA2 restricted tumor antigens is impaired by the oncogene HER2. Int J Cancer 128(2):390-401. doi:10.1002/ijc.25613